Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model

Aims Loss-of-function mutations in the hERG gene causes long-QT syndrome type 2 (LQT2), a condition associated with reduced IKr current. Four different mutation classes define the molecular mechanisms impairing hERG. Among them, Class 2 mutations determine hERG trafficking defects. Lumacaftor (LUM) is a drug acting on channel trafficking already successfully tested for cystic fibrosis and its safety profile is well known. We hypothesize that LUM might rescue also hERG trafficking defects in LQT2 and exert anti-arrhythmic effects. Methods and results From five LQT2 patients, we generated lines of induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) harbouring Class 1 and 2 mutations. The effects of LUM on corrected field potential durations (cFPD) and calcium-handling irregularities were verified by multi electrode array and by calcium transients imaging, respectively. Molecular analysis was performed to clarify the mechanism of action of LUM on hERG trafficking and calcium handling. Long-QT syndrome type 2 induced pluripotent stem cell-derived cardiomyocytes mimicked the clinical phenotypes and showed both prolonged cFPD (grossly equivalent to the QT interval) and increased arrhythmias. Lumacaftor significantly shortened cFPD in Class 2 iPSC-CMs by correcting the hERG trafficking defect. Furthermore, LUM seemed to act also on calcium handling by reducing RyR2S2808 phosphorylation in both Class 1 and 2 iPSC-CMs. Conclusion Lumacaftor, a drug already in clinical use, can rescue the pathological phenotype of LQT2 iPSC-CMs, particularly those derived from Class 2 mutated patients. Our results suggest that the use of LUM in LQT2 patients not protected by β-blockers is feasible and may represent a novel therapeutic option.

[1]  P. Schwartz,et al.  The KCNH2-IVS9-28A/G mutation causes aberrant isoform expression and hERG trafficking defect in cardiomyocytes derived from patients affected by Long QT Syndrome type 2. , 2017, International journal of cardiology.

[2]  M. Mura,et al.  Induced pluripotent stem cell technology: Toward the future of cardiac arrhythmias. , 2017, International journal of cardiology.

[3]  Stefano Severi,et al.  Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes , 2017, Cardiovascular research.

[4]  E. Deeks.  Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis , 2016, Drugs.

[5]  M. Ackerman,et al.  Calcium Revisited: New Insights Into the Molecular Basis of Long-QT Syndrome. , 2016, Circulation. Arrhythmia and electrophysiology.

[6]  M. Zaccolo,et al.  Correctors of mutant CFTR enhance subcortical cAMP–PKA signaling through modulating ezrin phosphorylation and cytoskeleton organization , 2016, Journal of Cell Science.

[7]  C. January,et al.  Molecular pathogenesis of long QT syndrome type 2 , 2016, Journal of arrhythmia.

[8]  Andrea Mazzanti,et al.  [2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death]. , 2015, Kardiologia polska.

[9]  A. Karma,et al.  Hyperphosphorylation of RyRs Underlies Triggered Activity in Transgenic Rabbit Model of LQT2 Syndrome , 2014, Circulation research.

[10]  A. Mehta,et al.  Phasic modulation of Wnt signaling enhances cardiac differentiation in human pluripotent stem cells by recapitulating developmental ontogeny. , 2014, Biochimica et biophysica acta.

[11]  P. Schwartz.  Cardiac sympathetic denervation to prevent life-threatening arrhythmias , 2014, Nature Reviews Cardiology.

[12]  A. Mehta,et al.  Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes. , 2014, Cardiovascular research.

[13]  Michael J Ackerman,et al.  The long QT syndrome: a transatlantic clinical approach to diagnosis and therapy. , 2013, European heart journal.

[14]  Susan S. Taylor,et al.  Integrins protect cardiomyocytes from ischemia/reperfusion injury. , 2013, The Journal of clinical investigation.

[15]  Michael J Ackerman,et al.  Impact of genetics on the clinical management of channelopathies. , 2013, Journal of the American College of Cardiology.

[16]  M. Kohlhaas,et al.  Calcium release microdomains and mitochondria. , 2013, Cardiovascular research.

[17]  Philip Wong,et al.  Pharmacoelectrophysiology of viral-free induced pluripotent stem cell-derived human cardiomyocytes. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[18]  Lia Crotti,et al.  Long-QT syndrome: from genetics to management. , 2012, Circulation. Arrhythmia and electrophysiology.

[19]  P. Negulescu,et al.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.

[20]  J. Clancy,et al.  Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation , 2011, Thorax.

[21]  Karl-Ludwig Laugwitz,et al.  Patient-specific induced pluripotent stem-cell models for long-QT syndrome. , 2010, The New England journal of medicine.

[22]  L. Jordaens,et al.  Who Are the Long-QT Syndrome Patients Who Receive an Implantable Cardioverter-Defibrillator and What Happens to Them?: Data From the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry , 2010, Circulation.

[23]  B. Horne,et al.  Nonsense Mutations in hERG Cause a Decrease in Mutant mRNA Transcripts by Nonsense-Mediated mRNA Decay in Human Long-QT Syndrome , 2007, Circulation.

[24]  D. Bers,et al.  Ca2+/Calmodulin–Dependent Protein Kinase Modulates Cardiac Ryanodine Receptor Phosphorylation and Sarcoplasmic Reticulum Ca2+ Leak in Heart Failure , 2005, Circulation research.

[25]  S. Reiken,et al.  Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Calum A MacRae,et al.  Risk stratification in the long-QT syndrome. , 2003, The New England journal of medicine.

[27]  D. Burkhoff,et al.  PKA Phosphorylation Dissociates FKBP12.6 from the Calcium Release Channel (Ryanodine Receptor) Defective Regulation in Failing Hearts , 2000, Cell.

[28]  S. Priori,et al.  Low penetrance in the long-QT syndrome: clinical impact. , 1999, Circulation.

[29]  W. Lederer,et al.  Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. , 1997, Science.

[30]  P. Greengard,et al.  Characterization of the interaction between DARPP-32 and protein phosphatase 1 (PP-1): DARPP-32 peptides antagonize the interaction of PP-1 with binding proteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Priori,et al.  Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. , 1995, Circulation.

[32]  J. Vandenbroucke,et al.  QT Interval Prolongation Predicts Cardiovascular Mortality in an Apparently Healthy Population , 1991, Circulation.

[33]  P. Schwartz,et al.  Idiopathic long QT syndrome: progress and questions. , 1985, American heart journal.

[34]  A. Malliani,et al.  The long Q-T syndrome. , 1975, American heart journal.